FrancophonIA/ELRC3.0 huggingface dataset:
English: DuoTrav contains two active substances, travoprost and timolol, which lower the pressure in the eye in different ways.
Maltese: DuoTrav fih żewġ sustanzi attivi, travoprost u timolol, li jbaxxu l-pressjoni fl-għajn b'modi differenti.
English: What is the risk associated with DuoTrav?
Maltese: X'inhu r-riskju assoċjat ma' DuoTrav?
English: For the full list of all side effects reported with DuoTrav, see the package leaflet.
Maltese: Għallista sħiħa tal-effetti sekondarji kollha rapportati bi DuoTrav, ara l-fuljett ta' tagħrif.
English: DuoTrav should not be used in people who may be hypersensitive (allergic) to travoprost, timolol (and other beta-blockers), or any of the other ingredients.
Maltese: DuoTrav m'għandux jintuża f'nies li jistgħu jkunu ipersensittivi (allerġiċi) għal travoprost, timolol (u beta-mblokkaturi oħrajn), jew għal xi sustanza oħra tiegħu.
English: DuoTrav may cause the iris of the eye to change colour (darken) and the eyelashes to thicken, darken or lengthen.
Maltese: DueTrav jista' jikkawża tibdil fil-kulur għall-iris (tiskura) u jġiegħel lix-xagħar tal-għajnejn jeħxien, jiskura jew jitwal.
English: The marketing authorisation is valid for an unlimited period.
Maltese: L-awtorizzazzjoni għat-tqegħid fis-suq hija valida għal perjodu mhux limitat.
English: The combination of the two active substances has an additive effect, reducing the pressure inside the eye more than either medicine alone.
Maltese: Il-kombinazzjoni taż-żewġ sustanzi attivi għandha effett addittiv, bit-tnaqqis tal-pressjoni fl-għajn aktar minn waħda mill-mediċini weħidha.
English: Timolol is a beta-blocker that works by reducing the production of fluid within the eye. Timolol has been used to treat glaucoma since the 1970's.
Maltese: Travoprost waħdu ġie awtorizzat fl-Unjoni Ewropea bħala Travatan sa mill-2001.
English: It was as effective as the two medicines given as separate eye drops, and as effective as eye drops containing both latanoprost and timolol.
Maltese: Kien effikaċi daqs iż-żewġ mediċini mogħtijin bħala qtar tal-għajnejn separati, u effikaċi daqs qtar tal-għajnejn li fihom kemm latanoprost kif ukoll timolol.
English: Oral use sachet (PET/OPA/alu/LDPE)
Maltese: Qartas (PET/OPA/alu/LDPE)
English: Powder for oral suspension
Maltese: Trab għal suspensjoni orali
English: 30 sachets + 1 mixing bottle + 30 single-use oral syringes + 1 screw cap with syringe-port capability
Maltese: 30 qartas + flixkun għat-taħlita + 30 siringa orali li jintużaw darba + tapp bil-kamin bil-possibbiltà ta' feles għas-siringa
English: MA (EU) number (Invented) name Strength
Maltese: Numru tal-MA (EU) Isem (ivvintat)
English: Pack size
Maltese: Qawwa
English: l Suspension (inactivated)
Maltese: Sospensjoni (inattivata)
English: Rabies virus, strain SAD Vnukovo-32
Maltese: Rabies virus, strejn SAD Vnukovo-32
English: Route of administrati on
Maltese: Mod ta' Amministrazzjoni
English: --1 Lyophilisate (live attenuated) Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15
Maltese: --1 Lijofiliżejt (attenwat haj) Canine arainfluenza type 2 virus, strejn CPiV-2-Bio 15
English: ≥ 2.0 IU***
Maltese: IU***/ml
English: ** Antibody micro agglutination-lytic reaction.
Maltese: * Tissue culture infectious dose 50%. ** Antibody micro agglutination-lytic reaction. *** International units.
English: Pharmaceutic al form
Maltese: Għamla Farmaċewtika
English: Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091
Maltese: Leptospira kirschneri serogrupp Grippotyphosa serovar Grippotyphosa, strejn MSLB 1091
English: Packagin g
Maltese: Qawwa
English: Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088
Maltese: Leptospira interrogans serogrupp Australis serovar Bratislava, strejn MSLB 1088
English: Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090
Maltese: Leptospira interrogans serogrupp Canicola serovar Canicola, strejn MSLB 1090
English: Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089
Maltese: Leptospira interrogans serogrupp Icterohaemorrhagiae serovar Icterohaemorrhagiae, strejn MSLB 1089
English: Strengt h
Maltese: Perjodu ta' Tiżmim
English: Packaging
Maltese: Ippakkjar
English: **Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.
Maltese: ** Qawwa Relattiva skont test ta' qawwa fil-ġrieden imqabbel ma' tilqima ta' referenza li ntweriet li hija effikaċi fin-nagħaġ.
English: EMEA Number Invented Name
Maltese: Numru ta' lEMEA
English: Content Package size
Maltese: Kontenut Daqs talpakkett
English: Withdrawal period
Maltese: Perijodu ta' Tiżmim
English: BACKGROUND INFORMATION
Maltese: INFORMAZZJONI TA' SFOND
English: London, 30 April 2009 EMEA/681319/2008
Maltese: Londra, 30 ta' April 2009 EMEA/681319/2009
English: EMEA/681318/2008-EN
Maltese: EMEA/681318/2008-MT
English: Xylazine, detomidine, medetomidine and romifidine are alpha2-adrenoreceptor agonists.
Maltese: Xylazine, detomidine, medetomidine u romifidine huma alpha2-adrenoreceptor agonists.
English: (International Non-Proprietary Name (INN): Xylazine, Medetomidine, Detomidine, Romifidine)
Maltese: Xylazine, Medetomidine, Detomidine, Romifidine)
English: Dr Anja Holm was appointed as Rapporteur and Dr Peter Ekström as Co-Rapporteur.
Maltese: Rapporteur u Dr Peter Ekström bħala Co-Rapporteur.
English: 1 Article 78 of Directive 2001/82/EC, as amended See Annex I for the complete list of concerned products
Maltese: 1 Artikolu 78 tad-Direttiva 2001/82/KE, kif emendata Ara l-Anness I għal-lista kompluta ta' prodotti konċernati
English: OPINION FOLLOWING AN ARTICLE 781 PROCEDURE FOR Veterinary medicinal products containing Alpha2-adrenoreceptor agonists2
Maltese: OPINJONI WARA PROĊEDURA SKONT L-ARTIKOLU 781 GĦAL Prodotti mediċinali veterinarji li fihom Alpha2-adrenoreceptor agonists2
English: The College Ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board, The Netherlands), in accordance with Article 78(1) of Directive 2001/82/EC, as amended by Directive 2004/28/EC, informed the EMEA by a letter dated 25 August 2006 of its intention to vary the marketing authorisation and to add a new precautionary measure for 21 veterinary medicinal products containing alpha2-adrenoreceptor agonists authorised in The Netherlands.
Maltese: Il-College Ter Beoordeling van Geneesmiddelen (Bord għall-Valutazzjoni tal-Mediċini, l-Olanda), skont l-Artikolu 78(1) tad-Direttiva 2001/82/KE kif emendata bid-Direttiva 2004/28/KE, informa lillEMEA permezz ta' ittra datata 25 ta' Awwissu 2006, bl-intenzjoni tiegħu li jvarja l-awtorizzazzjoni għat-tqegħid fis-suq u li jżid miżura ġdida ta' prekawzjoni għal 21 prodott mediċinali veterinarju li fihom alpha2-adrenoreceptor agonists awtorizzati fl-Olanda.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
Maltese: KUMITAT GĦALL-PRODOTTI MEDIĊINALI GĦAL UŻU VETERINARJU (CVMP)
English: The veterinarian experienced cardiovascular and central nervous system effects over a period of 3 days.
Maltese: Il-veterinarju esperjenza effetti kardjovaskulari u effetti fuq is-sistema nervuża ċentrali fuq perjodu ta' 3 ijiem.
English: The CVMP concluded that, on the basis of the available data, there is at present a potential risk to human health posed by the use of products containing alpha2-adrenoreceptor agonists, and issued a revised opinion on 12 November 2008.
Maltese: Is-CVMP ikkonkluda li, skont id-data disponibbli, fil-preżent hemm riskju potenzjali għas-saħħa talbniedem maħluq mill-użu ta' prodotti li fihom alpha2-adrenoreceptor agonists, u ħareġ opinjoni riveduta fit-12 ta' Novembru 2008.
English: During its December 2006 meeting, the CVMP, in light of the overall data submitted, additional data from the public domain and the scientific discussion within the Committee, adopted by consensus an opinion concerning the 21 veterinary medicinal products as authorised in the Netherlands.
Maltese: Waqt il-laqgħa tiegħu ta' Diċembru 2006, is-CVMP, fid-dawl tad-data globali ppreżentata, data addizzjonali mid-dominju pubbliku u d-diskussjoni xjentifika fi ħdan il-Kumitat, b'kunsens adotta opinjoni li tikkonċerna l-21 prodott mediċinali veterinarju kif awtorizzati fl-Olanda.
English: Alpha2-adrenoreceptor agonists are pharmaceutically active substances that are commonly used to induce effects such as sedation, analgesia and muscle relaxation.
Maltese: Alpha2-adrenoreceptor agonists huma sustanzi farmaċewtikament attivi li jintużaw komunement biex jikkaġunaw effetti bħal sedazzjoni, analġeżija u rilassament tal-muskoli.
English: The Committee reconfirmed Dr A. Holm as Rapporteur and Dr P. Ekström as Co-Rapporteur for the procedure.
Maltese: Holm bħala Rapporteur u lil Dr P.
English: Following further communication with the European Commission in years 2007 and 2008 on the opinion and the scope of the procedure, the CVMP in the July 2008 plenary meeting agreed to complete the procedure under Article 78 of Directive 2001/82/EC, as amended, for all marketing authorisations held in the EU for the 21 products containing alpha2-adrenoreceptor agonists initially notified and to revise the initial opinion accordingly.
Maltese: Wara aktar komunikazzjoni mal-Kummissjoni Ewropea fis-snin 2007 u 2008 dwar l-opinjoni u l-iskop tal-proċedura, is-CVMP, fil-laqgħa plenarja ta' Lulju 2008, qabel li jtemm il-proċedura skont lArtikolu 78 tad-Direttiva 2001/82/KE, kif emendata, għall-awtorizzazzjonijiet għal tqegħid fis-suq kollha li saru fl-UE għall-21 prodott li fihom alpha2-adrenoreceptor agonists li kienu notifikati inizjalment u li jirrevedi l-opinjoni inizjali għal din ir-raġuni.
English: The final opinion was converted into a Decision by the European Commission on 30 April 2009.
Maltese: L-opinjoni finali inbidlet f'deċiżjoni mill-Kummissjoni Ewropea fil-30 ta' April 2009.
English: Written responses were received by Marketing Authorisation Holders for 81 of the 108 notified authorisations held by a total of 66 Marketing Authorisation Holders by 16 September 2008.
Maltese: Il-MAHs irċevew risposti bilmiktub għal 81 mill-108 awtorizzazzjoni notifikata miżmuma minn total ta' 66 MAH sas-16 ta' Settembru 2008.
English: In accordance with Article 78(3) of Directive 2001/82/EC, as amended, the Committee for Medicinal Products for Veterinary Use (CVMP) is to give its opinion on the conclusions and intended risk management measures presented by the notifying Authority which in this procedure was the Dutch Medicines Evaluation Board.
Maltese: Skont l-Artikolu 78(3) tad-Direttiva 2001/82/KE, kif emendata, il-Kumitat għall-Prodotti Mediċinali għal Użu Veterinarju (CVMP) għandu jagħti l-opinjoni tiegħu dwar il-konklużjonijiet u l-miżuri intenzjonati għall-ġestjoni tar-riskji ppreżentati mill-Awtorità li qed tinnotifika li f'din il-proċedura kienet il-Bord għall-Valutazzjoni tal-Mediċini tal-Olanda.
English: The extrapolation of the proposed warnings for one alpha2adrenoreceptor agonist to other alpha2-adrenoreceptor agonists was considered justified, since the pharmacological mode of action is the same and because several of the substances have shown similar effects in humans.
Maltese: L-estrapolazzjoni tat-twissijiet proposti għal alpha2-adrenoreceptor agonist wieħed għal alpha2-adrenoreceptor agonists oħrajn kienet ikkunsidrata bħala ġustifikata, billi l-mod ta' azzjoni farmakoloġika huwa l-istess u minħabba li ħafna mis-sustanzi wrew effetti simili fuq ilbnedmin.
English: On 13 September 2006 the procedure was initiated by adoption of a list of questions to be put to the concerned Marketing Authorisation Holders.
Maltese: Fit-13 ta' Settembru 2006, il-proċedura inbdiet b'adozzjoni ta' lista ta' mistoqsijiet li jridu jsiru lidDetenturi tal-Awtorizzazzjoni għat-Tqegħid fis-Suq konċernati.
English: The basis for the notification was a suspected adverse reaction report received in The Netherlands after a veterinarian accidentally injected himself with the product Sedivet, which contains romifidine as the active ingredient.
Maltese: Il-bażi għal din in-notifika kien rapport dwar reazzjoni mhux mixtieqa suspettata li wasal l-Olanda wara li veterinarju aċċidentalment injetta lilu nnifsu bil-prodott Sedivet, li fih romifidine bħala ssustanza attiva.
English: The Committee considered that specific precautionary measures should be reflected in the product literature of concerned products containing alpha2-agonists.
Maltese: Il-Kumitat ikkunsidra li l-miżuri speċifiċi ta' prekawzjoni għandhom ikunu riflessi fl-informazzjoni dwar il-prodotti konċernati li fihom alpha2-agonists.
English: powder: 3 ml solvent: 5 ml
Maltese: trab: 3 ml solvent: 5 ml
English: 1 vial + 1 vial
Maltese: Kunjett 1 + Kunjett 1
English: 0.9 mg Powder and solvent for solution for injection
Maltese: 0.9 mg Trab u solvent għal soluzzjoni għal injezzjoni
English: Packaging
Maltese: Daqs talpakkett
English: Intralesional use powder: vial (glass) solvent: vial (glass)
Maltese: Kunjett (ħġieġ) solvent:
English: EU Number
Maltese: Numru ta' Proċedura ta' l-EU
English: Route of Administration
Maltese: Użu intrależjonali trab:
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 August 2015
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 ta' Awwissu 2015
English: The company wanted the authorisation to be recognised in other EU Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom).
Maltese: Il-kumpanija riedet li l-awtorizzazzjoni tiġi rikonoxxuta fi Stati Membri tal-UE oħrajn (l-‘Istati Membri kkonċernati', f'dan ilkaż l-Awstrija, il-Belġju, il-Bulgarija, il-Kroazja, Ċipru, ir-Repubblika Ċeka, l-Estonja, il-Finlandja, ilĠermanja, il-Greċja, l-Iżlanda, l-Irlanda, l-Italja, il-Latvija, il-Litwanja, in-Netherlands, il-Polonja, ilPortugall, ir-Rumanija, is-Slovakkja, is-Slovenja, l-Iżvezja u r-Renju Unit).
English: Outcome of a procedure under Article 33(4) of Directive 2001/82/EC, as amended
Maltese: Eżitu ta' proċedura skont l-Artikolu 33(4) tad-Direttiva 2001/82/KE, kif emendata
English: What are the conclusions of the CVMP?
Maltese: X'inhuma l-konklużjonijiet tas-CVMP?
English: The vaccine contains five formaldehyde-inactivated strains of Actinobacillus pleuropneumoniae.
Maltese: Il-vaċċin fih ħames razez inattivati minn formaldeid ta' Actinobacillus pleuropneumoniae.
English: Duration of immunity was established for both serotypes (1 and 2) up to 16 weeks after vaccination according to the results of relevant challenge studies.
Maltese: It-tul tal-immunità ġie stabbilit għaż-żewġ serotipi (1 u 2) għal massimu ta' 16-il ġimgħa wara ttilqim, skont ir-riżultati ta' studji ta' sfida relevanti.
English: Coglapix is an inactivated bacterial vaccine against porcine actinobacillosis.
Maltese: Coglapix huwa vaċċin batteriku inattivat kontra aktinobaċillożi porċina.
English: The vaccine is intended for active immunisation of pigs against pleuropneumonia caused by A. pleuropneumoniae serotypes 1 and 2, in order to reduce the clinical signs and lung lesions associated with the disease.
Maltese: Il-vaċċin huwa maħsub għallimmunizzazzjoni attiva tal-ħnieżer kontra plewropnewmonja kkawżata mis-serotipi 1 u 2 ta' A. pleuropneumoniae, sabiex jitnaqqsu s-sinjali kliniċi u l-leżjonijiet fil-pulmun assoċjati mal-marda.
English: On 3 June 2015, the European Medicines Agency (the Agency) completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Coglapix suspension for injection for pigs.
Maltese: Fit-3 ta' Ġunju 2015, l-Aġenzija Ewropea għall-Mediċini (l-Aġenzija) temmet proċedura ta' arbitraġġ wara nuqqas ta' qbil fost l-Istati Membri tal-Unjoni Ewropea (UE) fir-rigward tal-awtorizzazzjoni talmediċina Coglapix sospensjoni għal injezzjoni għall-ħnieżer.
English: However, the Member States were not able to reach an agreement and the National Food Chain Safety Office of Hungary referred the matter to the CVMP for arbitration on 24 October 2014.
Maltese: Madankollu, l-Istati Membri ma kinux kapaċi jaslu għal ftehim u l-Uffiċċju Nazzjonali tas-Sigurtà talKatina Alimentari rrefera l-kwistjoni lis-CVMP għal arbitraġġ fl-24 ta' Ottubru 2014.
English: Ceva-Phylaxia Veterinary Biologicals Co. Ltd. submitted an application for Coglapix for mutual recognition on the basis of the initial authorisation granted by Hungary.
Maltese: Ltd issottomettiet applikazzjoni għal Coglapix għal rikonoxximent reċiproku abbażi tal-awtorizzazzjoni inizjali li ngħatat mill-Ungerija.
English: The product information for Coglapix in Hungary should also be amended.
Maltese: L-informazzjoni tal-prodott għal Coglapix fl-Ungerija għandha tiġi emendata wkoll.
English: What is Coglapix suspension for injection for pigs?
Maltese: X'inhu Coglapix sospensjoni għal injezzjoni għall-ħnieżer?
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Coglapix outweigh its risks, and the marketing authorisation granted in Hungary can be recognised in other Member States of the EU (see below).
Maltese: Il-Kumitat għall-Prodotti Mediċinali għallUżu Veterinarju (CVMP) tal-Aġenzija kkonkluda li l-benefiċċji ta' Coglapix huma akbar mir-riskji tiegħu, u l-awtorizzazzjoni għat-tqegħid fis-suq li ngħatat fl-Ungerija tista' tiġi rikonoxxuta fi Stati Membri oħrajn tal-UE (ara hawn isfel).
English: Therefore, based on evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of Coglapix outweigh its risks, and recommended that the marketing authorisation be granted in all concerned Member States.
Maltese: Għalhekk, abbażi tad-data disponibbli bħalissa u d-diskussjoni xjentifika fi ħdan il-Kumitat, is-CVMP ikkonkluda li l-benefiċċji ta' Coglapix huma akbar mir-riskji tiegħu u rrakkomanda li jingħata lawtorizzazzjoni għat-tqegħid fis-suq fl-Istati Membri kkonċernati kollha.
English: 10 vials (monodose)
Maltese: 10 dożi)
English: Content (concentration) Pack size
Maltese: Kontenut (konċentrazzjoni)
English: MA (EU) number (Invented) name
Maltese: Numru ta' l-EU
English: 10 vials (multidose: 10 doses)
Maltese: 10 kunjetti (għadd ta' dożi:
English: Tietokuja 4, 00330 Helsinki, Finland
Maltese: Tietokuja 4, 00330 Helsinki, IlFinland
English: Instituto Pasteur de Lisboa, S.A.
Maltese: Instituto Pasteur de Lisboa, S.A. Rua Dr.
English: Rua Dr. António Loureiro Borges, 2
Maltese: António Loureiro Borges,
English: Intravenous (Infusion, Injection)
Maltese: Ġol-vina (Infużjoni, Injezzjoni)
English: Via Nettunense, 90 Aprilia (LT), 04011, Italy
Maltese: Aprilia (LT), 04011, Italy
English: Slovak Republic
Maltese: Repubblika Slovakka
English: John Wyeth & Brother Limited (trading as Wyeth Pharmaceuticals) Huntercombe Lane South Taplow, Maidenhead, Berks, SL6 0PH United Kingdom
Maltese: John Wyeth & Brother Limited (isem kummerċjali Wyeth Pharmaceuticals) Huntercombe Lane South Taplow, Maidenhead, Berks, SL6 0PH United Kingdom
English: 4 g piperacillin equivalent to 4.17 g piperacillin sodium
Maltese: 4 g ta' piperacillin ekwivalenti għal 4.17 g ta' piperacillin sodium
English: John Wyeth & Brother Limited (trading as Wyeth Pharmaceuticals) Huntercombe Lane South Taplow
Maltese: John Wyeth & Brother Limited (isem Kummerċjali Wyeth Pharmaceuticals) Huntercombe Lane South Taplow
English: Pfizer, Coeur DéfenseTour A - La Défense 4 92931 PARIS LA DEFENSE Cedex
Maltese: Pfizer, Coeur DéfenseTour A - La Défense 4
English: TAZOCIN 4,0g/0,5g pulveris injekciju vai infūziju šķīduma pagatavošanai
Maltese: TAZOCIN 4,0g/0,5g pulveris injekciju vai infūziju ķīduma pagatavoanai
English: Coeur DéfenseTour A - La Défense 4 92931 PARIS LA DEFENSE Cedex
Maltese: 92931 PARIS LA DEFENSE Cedex, France
English: Intravenous use 2 g piperacillinum / 0,25 g tazobactamum
Maltese: 2 g ta' piperacillinum / 0,25 g ta' tazobactamum
English: Intravenous use 4 g piperacillinum / 0,5 g tazobactamum
Maltese: 4 g ta' piperacillinum / 0,5 g ta' tazobactamum
English: 2,085 g sodium piperacillin + 268,30 mg sodium tazobactam
Maltese: 2,085 g ta' sodium piperacillin + 268,30 mg ta' sodium tazobactam
English: G/VIAL
Maltese: G/KUNJETT
English: 0.5 g tazobactam equivalent to 0.5366 g tazobactam sodium
Maltese: 0.5 g ta' tazobactam ekwivalenti għal 0.5366 g ta' tazobactam sodium
English: to piperacillin 4 g) 4170 mg
Maltese: Piperacillin sodium (ekwiv. għal piperacillin 4g) 4170 mg
English: Tazocin® 4 g/ 500 mg 4 g/500mg
Maltese: Tazocin® 4 g/ 500 mg
English: to tazobactam 500 mg) 536,6 mg
Maltese: Tazobactam sodium (ekwiv. għal tazobactam 500 mg) 536,6 mg
English: 4,170 g sodium piperacillin + 536,60 mg sodium tazobactam
Maltese: 4,170 g ta' sodium piperacillin + 536,60 mg ta' sodium tazobactam
English: Infusion
Maltese: Infużjoni
English: to tazobactam 250 mg) 268,3 mg
Maltese: Tazobactam sodium (ekwiv. għal tazobactam 250 mg) 268,3 mg
English: Sodium piperacillin and sodium tazobactam, equivalent to 2 g piperacillin and 250 mg tazobactam.
Maltese: Sodium piperacillin u sodium tazobactam, ekwivalenti għal 2 g ta' piperacillin u 250 mg ta' tazobactam.
English: 2.00 g as piperacillin sodium and tazobactam 0.25 g as tazobactam sodium.
Maltese: 2.00 g bħala piperacillin sodium u tazobactam 0.25 g bħala tazobactam sodium.
English: 4.00 g as piperacillin sodium and tazobactam 0.5 g as tazobactam sodium.
Maltese: 4.00 g bħala piperacillin sodium u tazobactam 0.5 g bħala tazobactam sodium.
English: TAZOCIN 2g/0.25g contains 2 active ingredients; piperacillin 2g and tazobactam 0.25g both present as sodium salts.
Maltese: TAZOCIN 2 g/0.25 g fih 2 sustanzi attivi piperacillin 2 g u tazobactam 0.25g it-tnejn preżenti bħala mluħa tas-sodium.
English: Sodium piperacillin and sodium tazobactam, equivalent to 4 g piperacillin and 500 mg tazobactam
Maltese: Sodium piperacillin u sodium tazobactam, ekwivalenti għal 4 g ta' piperacillin u 500 mg ta' tazobactam
English: 0.5366 g tazobactam sodium equivalent to 0.500 g tazobactam and 4.170 g piperacillin sodium equivalent to 4.00 g piperacillin
Maltese: 0.5366 g ta' tazobactam sodium ekwivalenti għal 0.500 g ta' tazobactam u 4.170 g ta 'piperacillin sodium ekwivalenti għal 4.00 g ta' piperacillin
English: 2 g/0,25 g
Maltese: 2,00/0,25g
English: Tazobactam.sodium 0,2683 g
Maltese: Piperacillin. sodium 2.085 g Tazobactam.sodium 0,2683 g
English: 2g/0.25g
Maltese: TAZOCIN 2g/0.25g
English: 2.085 g sodium piperacillin equivalent to 2 g piperacillin and 0.2683 g sodium tazobactam equivalent to 0.250 g tazobactam.
Maltese: 2.085 g ta' sodium piperacillin ekwivalenti għal 2 g ta' piperacillin u 0.2683 g ta' sodium tazobactam ekwivalenti għal 0.250 mg ta' tazobactam.
English: TAZOCILLINE 2 g/250 mg, poudre pour solution pour perfusion
Maltese: 2 g/250 mg, poudre pour solution pour perfusion
English: Piperacillin (in the form of piperacillin sodium) 4 g Tazobactam (in the form of tazobactam sodium) 0.50 g
Maltese: Piperacillin (fis-sura ta' piperacillin sodium) 4 g Tazobactam (fis-sura ta' tazobactam sodium) 0.50 g
English: TAZOCIN 4g/0.5g contains 2 active ingredients; piperacillin 4g and tazobactam 0.5g both present as sodium salts.
Maltese: TAZOCIN 4 g/0.5 g fih 2 sustanzi attivi piperacillin 4 g u tazobactam 0.5g it-tnejn preżenti bħala mluħa tas-sodium.
English: Tazocin 4,5 g injekció 4.5g
Maltese: Tazocin 4,5 g injekció
English: Piperacillin (in the form of piperacillin sodium) 2 g Tazobactam (in the form of tazobactam sodium) 0.25 g
Maltese: Piperacillin (fis-sura ta' piperacillin sodium) 2 g Tazobactam (fis-sura ta' tazobactam sodium) 0.25 g
English: to piperacillin 2g) 2085 mg Tazobactam sodium (equiv.
Maltese: Piperacillin sodium (ekwiv. għal piperacillin 2g) 2085 mg
English: 2.085 g of piperacillin sodium equivalent to 2 g of piperacillin and 0.2683 g of tazobactam sodium equivalent to 250 mg of tazobactam
Maltese: 2.085 g ta' piperacillin sodium ekwivalenti għal 2 g ta' piperacillin u 0.2683 g ta' tazobactam sodium ekwivalenti għal 250 mg ta' tazobactam
English: Tazobactam .sodium 0,5366 g
Maltese: Piperacillin. sodium 4.170 g Tazobactam .sodium 0,5366 g